ADC Therapeutics Director Azelby Sells Shares Amid Price Target Cut
Robert Azelby sells $20,215 in ADC Therapeutics shares for tax reasons; holds 53,005 shares. Investors eye insider actions for future ...
- Latest
- Trending
Robert Azelby sells $20,215 in ADC Therapeutics shares for tax reasons; holds 53,005 shares. Investors eye insider actions for future ...
"Iontronic tech shows promise in slowing malignant brain tumor growth by continuously delivering low-dose drugs, bypassing the blood-brain barrier."
"Day One Biopharmaceuticals enhances pipeline, acquiring global rights to promising PTK7-targeting cancer drug DAY301, begins trial soon."
Catch up on biotech headlines: Zentalis faces FDA hold, Aerovate's major setback, Merck's new vaccine, and promising trials by Intra-Cellular ...
"Discover 7 breakthrough biotech stocks poised to boost your portfolio in a sector projected to reach $521.6B by 2033. Learn ...
Aerovate Therapeutics stock downgraded by BTIG after AV-101 trial setback; mixed analyst views and future pivotal readouts crucial for investors.
Roche's Hemlibra braces for fierce competition from Novo Nordisk's mim8, as analysts give mixed ratings and forecasts on Roche's strategic ...
Bitcoin dominates with 60% of crypto transaction volume. TRON and Ethereum follow. 70% of drug precursor sales linked to 11 ...
Avidity Biosciences sees share ownership shift as MacLean reduces holding under Rule 10b5-1 Plan; positive sector developments bolster outlook.
Arthur A. Levin sells 40K Avidity shares; BofA ups target to $45 as FDA advances myotonic dystrophy treatment. AI-assisted article ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.